Down 14%, FDA Concerns Crush Nektar

The Food and Drug Administration has been cracking down on a class of constipation drugs because of fears around potential cardiovascular risks. This additional regulatory oversight has big implications for a drug still in the pipeline from Nektar Therapeutics (Nasdaq: NKTR  ) , and it brought the company's shares down 14% on Monday. In this video, Motley Fool health care analyst Brenton Flynn talks about the market for these drugs, and how the FDA's concerns are impacting not only Nektar but several other companies operating in this space.

While you can certainly make huge gains in biotech and pharmaceuticals, the story of Nektar Therapeutics shows that this sector can also be associated with huge risk. That's why we think the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 13, 2012, at 11:47 AM, Hope4GoodFuture wrote:

    Check out Adam Feuerstein's comment from The Street.com

    "Faced with a failed phase III trial of its critically important opioid constipation drug, AstraZeneca may have embarked on a hunt to retrieve additional data from the "non-retrievable" patient. "Retrieved" data found. Database unlocked. "Retrieved" data added."

    Also, "The 12.5 mg dose of naloxegol failed badly with a p value of 0.202 while the 25 mg dose barely squeaked into victory lane with a p value of 0.021. [The trial required a p value less than 0.025 to reach statistical significance.]"

    The issue may be much worse for NKTR than simply being tainted by other companies' FDA issues.

Add your comment.

DocumentId: 2109227, ~/Articles/ArticleHandler.aspx, 7/25/2014 8:38:29 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement